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It is estimated that approximately 564 830 Americans died from cancer in 2006, correspondaing to over 1500 deaths per day, with lung cancer 
being among the ten leading cancer types.1 A total of 
1.2 million cancer deaths worldwide were attributed 
to lung cancer in 2002.2 Smoking mainly causes lung 
cancer; 95% of patients with lung cancer are smokers. 
The mortality is high, with a 5ayear crude survival from 
5% to 15%. Oneaquarter of the patients have small cell 
lung cancer and three quarters have nonasmall cell lung 
cancer (NSCLC), mainly squamous cell carcinoma, ada
enocarcinoma and large cell carcinoma.3 
Only a minority of patients with NSCLC are suita
able candidates for radical curative treatment; the maa
jority present with locally advanced or metastatic disa
ease at diagnosis and can obtain only a modest survival 
benefit from palliative platinumabased chemotherapy 
with or without radiotherapy. The prognosis for such 
patients is poor, with 5ayear survival rates of less than 
10%.4 Median survival for patients with locally ada
vanced disease or metastatic disease is 18 and 9 months, 
respectively.5 For firstaline treatment of patients with 
unresectable advanced (Stage IIIb/IV) NSCLC, platia
numabased doublets are standard.6,7 The introduction 
of thirdageneration cytotoxic agents (such as paclitaxel, 
docetaxel, gemcitabine, vinorelbine and irinotecan) 
achieved improvements in tumor response and tolera
ability, but only modest improvements in survival, and 
it may be that chemotherapy has reached its maximum 
potential.8a10
Recent therapies for NSCLC that are under intense 
development target novel cellular entities, such as epia
dermal growth factor receptor (EGFR) and vascular 
endothelial growth factor (VEGF),3,11 which was origia
nally discovered in the 1980s.12a14 VEGF is expressed 
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in normal tissues, and in almost every type of human 
tumor. Its expression is seen in alveolar macrophages, 
normal bronchiolar and differentiated columnar epia
thelial cells.15 VEGF increases permeability by inducing 
endothelial fenestrations, thus allowing the leakage of 
plasma proteins into the extravascular tissue and proa
moting the creation of a fibrinalike microenvironment.16 
This microenvironment serves as the foundation for 
neovascularization, tumor growth, propagation, and 
metastasis.17 Several studies indicate a correlation bea
tween VEGF expression, microvessel density (MVD) 
and poor prognosis in patients with NSCLC.18 Youn et 
al reported that a high VEGF level correlated with high 
MVD, short survival and early postoperative relapse.19 
Ushijima et al found that high MVD values carried an 
especially poor prognosis when associated with a high 
expression of VEGF.20
Bevacizumab (Avastin, F. HoffmannaLa Roche 
Ltd, Basel, Switzerland) is a recombinant humanized 
monoclonal antibody against VEGF.21 Preclinical in 
vivo models demonstrate that bevacizumab inhiba
its growth of a variety of human cancer cell lines in a 
doseadependent manner.22,23 In addition, by eliminating 
excess VEGF, newly formed tumor vessels become less 
permeable, resulting in a reduction of interstitial presa
sure. It has been shown that the latter effect increases 
the diffusion of chemotherapeutic drugs in the tumor 
and perhaps potentiates their activity.24
A randomized phased II study suggested the benefit 
of adding bevacizumab to standard chemotherapy for 
advanced NSCLC.10 These results led to the incorporaa
tion of bevacizumab in the treatment of such patients at 
our institution when possible, before its final regulatory 
approval by the European authorities. Subsequently, 
the confirmatory phase III study was published, further 
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supporting our practice.23 We present hereby a retroa
spective analysis of the outcomes of our early cohort of 
NSCLC patients who received bevacizumab, aiming at 
better characterizing the feasibility, safety and efficacy 
of bevacizumab in such patients.
PATIENTS AND METHODS
The study population included male and female paa
tients 18 years of age or older who had stage IIIB or 
IV, advanced or recurrent metastatic NSCLC, and had 
received a bevacizumab combination, on a compassiona
ate basis, before its regulatory approval. The decision on 
the use of bevacizumab was based on clinical judgment 
and the permission for such a compassionate use by the 
Hellenic Drug Organization (the central regulatory 
agency). Patients who had received prior therapy with 
various chemotherapeutic regimens were included in 
the study; however, the majority of patients were chea
motherapy naïve. There was no intentional exclusion of 
patients from receiving bevacizumab other than serious 
coamorbid conditions, according to clinical judgment 
and centrally located squamous cell cancer.  
Good clinical practice standards applied to our 
cohort. Pretreatment evaluation included a complete 
medical history, physical examination and standard 
laboratory examinations (full blood count, biochemical 
profile, prothrombin time, international normalized raa
tio, and partial thromboplastin time). CT or MRI of the 
chest, abdomen and brain were taken, and performance 
status was assessed according to Eastern Cooperative 
Oncology Group (ECOG) guidelines. A complete 
blood count was obtained regularly. An interim medical 
history, physical examination, and the laboratory tests 
listed above were repeated prior to the start of each 
cycle of therapy. Tumor assessment with imaging was 
performed every 6 weeks while on therapy and every 8 
weeks after completion; responses were determined by 
the investigators according to WHO criteria;25 stability 
required a minimum of 12 weeks.
Treatment plan
Every patient received bevacizumab 15 mg/kg on day 
1 every 3 weeks, along with standard chemotherapeutic 
regimens including carboplatinapaclitaxel, carboplatina
pemetrexed, platinum with gemcitabine, docetaxelabased 
chemotherapy, and erlotinib. Because bevacizumab was 
not approved for NSCLC during the study period, it was 
commercially provided after communication with regulaa
tory authorities and the patient’s insurance company. Its 
use was justified by existing clinical evidence, as the best 
available palliative treatment, on a compassionate basis. 
Finally, growth factor was administered on a peraneed baa
sis and relatively liberally; 17 patients received leukocyte 
colonyastimulating factor at some point.
Statistical analysis
The primary objective of the study was to assess the 
impact of bevacizumab in combination with various 
chemotherapeutic regimens on patient outcomes in a 
preliminary manner. Main endpoints included the dea
scription of toxicity outcomes on all patients; secondary 
endpoints included the median overall (OS) and proa
gressionafree survival (PFS) rates and clinical response 
rates of patients receiving firstaline treatment. Data 
are expressed as median and minimumamaximum for 
continuous variables and as percentages for categorical 
data. OS and PFS were estimated with the Kaplana
Meier productalimit method.26 All tests were twoasided 
with a 95% significance level. The statistical analysis 
was carried out using the statistical package SPSS vera
sion 15.00 (Statistical Package for the Social Sciences, 
SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
The 20 patients with NSCLC treated at our departa
ment between April 2005 and August 2007 and rea
viewed for this study included 16 (80%) males and 4 
(20%) females with a median age of 54.5 years (range, 
35a75 years) (Table 1). The majority of patients had 
stage IV disease. All patients had confirmed adenocara
cinoma of the lung with the exception of one patient 
who had relapsed after lobectomy with peripherally 
located squamous cell carcinoma and another who had 
adenoid cystic carcinoma. Due to local insurance rea
strictions, procurement of bevacizumab was feasible 
for approximately one quarter of the otherwise eligible 
patients who visited our clinic.  
At therapy initiation, 17 patients (85%) were chea
motherapy naïve and therefore on firstaline treatment. 
The remaining 3 patients (15%) were on secondaline 
treatment. In addition to bevacizumab, 9 patients 
(45%) received a chemotherapeutic combination of 
carboplatin/paclitaxel, 3 patients (15%) a combination 
of carboplatin/pemetrexed, 3 patients (15%) received 
docetaxelabased chemotherapy, 2 patients (10%) rea
ceived a combination of platinum/gemcitabine, 1 
patient (5%) received a combination of carboplatin/
gemcitabine, 1 patient (5%) received erlotinib, and 1 
patient (5%) received a combination of cetuximab/
irinotecan. Three patients (15%) had an ECOG pera
formance status (PS) of 0, 11 patients (55%) had a 
PS of 1, 5 patients (25%) had a PS of 2 and 1 patient 
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(5%) had a PS of 3. For all treated patients, the median 
number of therapy cycles administered was 6 (range, 
1a18). The median followaup of this cohort was 6.1 
months (range, 1a26).
Toxicity
In general, bevacizumab was well tolerated by most 
patients. No thrombotic events were noted. Grade 2 
hypertension occurred in 3 patients. Uncomplicated 
Table 1. Baseline patient and disease characteristics.
No. of patients 
(n=20) %
Median age (years) 54.5
Range 35-75
Gender
Male 16 80
Female 4 20
Disease stage
IIIB 2 10
IV 18 90
Regimen received
Carboplatin/
paclitaxel 9 45
Carboplatin/
pemetrexed 3 15
Docetaxel based 3 15
Cisplatin/
gemcitabine 2 10
Carboplatin/
gemcitabine 1 5
Erlotinib 1 5
Cetuximab/
irinotecan 1 5
Line of treatment
1st 17 85
2nd 3 15
ECOG* performance 
status
0 3 15
1 11 55
2 5 25
3 1 5
*ECOG: Eastern Cooperative Oncology Group
Table 2. Treatment-related adverse events.
No. of patients (n=20)
Grade <3 Grade >3
Hypertension 3 (15%) -
Epistaxis 5 (25%) -
Gingival bleeding 1 (5%) -
Retinal bleeding 1 (5%) -
Fatigue - 1 (5%)
Proteinuria - -
Neutropenia - -
Pulmonary abscess/
TE fistula 1 (5%)
TE: Tracheoesophageal
Table 3. Response rates (patients on first-line treatment (n=17).
No. of patients %
Response 
(WHO criteria)
Complete 2 11.8
Partial 6 35.3
Overall 8 47.1
Stable disease 6 35.3
Progressive disease 1 5.9
Non estimable 2 11.8
Table 4. Overall survival and progression-free survival (patients 
on first-line treatment (n=17).
95% Confidence 
interval
Overall survival
Median (months) 14 (4.8-23.2)
6 month 79.8%
12 month 52.4%
24 month 20.9%
Progressive-free 
survival
Median (months) 10.2 (4.3-16.1)
6 month 78.4%
12 month 48.8%
24 month 16.3%
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Figure 1. Kaplan-Meier estimate of overall survival (OS) for patients with NSCLC treated 
with bevacizumab + chemotherapy. Survival estimates (%) at 6, 12 and 24 months are 
shown in boxes (patients on first-line treatment, n=17).
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Figure 2. Kaplan-Meier estimate of progression-free survival (PFS) for patients with 
NSCLC treated with bevacizumab + chemotherapy. Survival estimates (%) at 6, 12 and 24 
months are shown in boxes (patients on first-line treatment, n=17).
epistaxis was reported in 5 patients and one patient dea
veloped mild gingival bleeding. There were no episodes 
of febrile neutropenia or proteinuria (Table 2). Overall, 
serious toxicity possibly related to bevacizumab admina
istration was observed in one case. 
Response, overall survival and progression free 
survival rates
Of the 17 patients on firstaline treatment, 2 patients 
(11.8%) achieved a complete response and 6 patients 
(35.3%) achieved a partial response (overall response 
rate, 47.1%). Stable disease was observed in 6 patients 
(35.3%) and 1 patient (5.9%) progressed (Table 3). 
The 1ayear overall survival rate was 52.4% and the 
median OS was 14 months (range, 4.8a23.2 months) 
(Table 4, Figure 1). The 12amonth PFS rate was 48.8% 
and the median PFS was 10.2 months (range, 4.3a16.1 
months) (Table 4, Figure 2).
DISCUSSION
The benefit of adding bevacizumab to standard treata
ment for unresectable NSCLC is by now well docua
mented. In E4599, a phase III study of bevacizumab in 
NSCLC, Sandler et al showed that the median overa
all survival was 12.3 months in the group of patients 
who received paclitaxelacarboplatinabevacizumab, as 
compared to 10.3 months in the paclitaxelacarboplata
in group (P=.003). Survival rates were 51% in the paa
clitaxelacarboplatinabevacizumab group as compared 
to 44% in the paclitaxelacarboplatin group at 1 year 
and 23%, as compared to 15%, respectively, at 2 years. 
The median PFS was also significantly improved in 
the paclitaxelacarboplatinabevacizumab group (6.2 
months, as compared with 4.5 months in the paclia
taxelacarboplatin group). Among 773 patients with 
measurable disease, the addition of bevacizumab to 
paclitaxel and carboplatin improved the response 
rate; 59 of 392 patients (15%) in the paclitaxelacara
boplatin group had a response, as compared with 133 
of 381 patients (35%) in the paclitaxelacarboplatina
bevacizumab group (P<.001).27 
In another randomized, phase II trial by Johnson 
and associates comparing carboplatin and paclitaxel 
with or without bevacizumab at two dose levels (7.5 
mg/kg versus 15mg mg/kg) in 99 patients with una
treated advanced or metastatic nonasmall cell lung cana
cer, higher response rates (31.5% versus 18.8%), longer 
median time to progression (7.4 versus 4.2 months, 
P=.023), and longer survival (17.7 versus 14.9 months, 
P=.63) were demonstrated in patients receiving the 
higheradose (15 mg/kg) bevacizumab. A total of 19 paa
tients originally receiving placebo with chemotherapy 
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were crossed over to bevacizumab at the time of disease 
progression, with a 1ayear survival rate of 47%.28,29 
The results of our uncontrolled and retrospective 
analysis of the compassionate use of bevacizumab in 
a cohort of patients with advanced NSCLC treated at 
our institution are consistent with the aboveadescribed 
benefit of bevacizumab in this population. The observed 
overall survival is in line with the report of the randoma
ized phase III study while the response rate observed 
is extremely encouraging and exceeds expectations. 
In addition, the durability of responses and the overa
all deceleration of the expected pace of the disease are 
particularly rewarding, and in retrospect justified the 
enthusiasm regarding the initiative to use bevacizumab 
regimens in our patients, before its regulatory approval. 
Apparently, this therapeutic option was facilitated by 
the experience of our center and our investigators in the 
use of bevacizumab in colon cancer patients, over the 
last 4 years. 
Our study results are limited by the relatively small 
number of patients who received offalabel bevacizumab 
therapy for the treatment of NSCLC; thus any conclua
sions should be drawn with caution. Nevertheless, our 
study illustrates a preliminary experience in patients 
with lung cancer, in a real world clinical setting, outside 
the rigor and beyond the limitations of a restricted trial 
design. In fact, several of our patients would have been 
eliminated from clinical studies. Regarding the safety 
aspect of the regimen studied, our experience demona
strated a toxicity profile that did not diverge from the 
expected. In particular, although bevacizumab was prea
viously reported to increase the rate of neutropenia, 
there was no neutropenic complication in our cohort. 
This was certainly facilitated by the use of growth faca
tors, according to the judgment of the treating physia
cian. In addition, the incidence of hypertension was low 
and this complication was relatively easily managed. 
It is also noteworthy that one case of fatal pulmonary 
hemorrhage occurred several months after bevacizuma
ab discontinuation, and is of unclear causal relationship 
with its administration. That patient had suffered many 
complications and had received mediastinal irradiation 
at a site of a recent infection, notwithstanding the presa
ence of a foreign body, namely an esophageal stent. Fatal 
hemorrhages may occur in patients with lung cancer, 
even without the use of bevacizumab. Although the fatal 
hemorrhage may have not been related to bevacizumab 
per se, the development of the tracheoesophageal fistula 
on the basis of a pulmonary abscess may well be related. 
The proper healing of the esophageal wall adjacent to 
the abscess may have been impaired by the circulating 
bevacizumab and may have led to the formation of the 
fistula. Such a patient with centrally located lesions 
adjacent to major vessels might have been eliminated 
from certain clinical studies such as the AVAIL study, 
but he would have been included in the ECOG study. 
Nevertheless, despite concerns over pulmonary hemora
rhage in patients receiving bevacizumab in the E4599 
study,27 no statistically significant difference in pulmoa
nary hemorrhage between the two arms was proven. 
Despite the unfortunate outcome of the one patient 
described, the addition of bevacizumab to standard 
chemotherapeutic regimens was otherwise well tolera
ated and appeared to yield highly beneficial outcomes 
for this cohort of patients. Thus, our experience is in 
agreement with the reports of previously conducted 
prospective studies, encouraging us to continue the use 
of bevacizumab in the adjuvant setting, in patients with 
nonasquamous, NSCLC. Nevertheless, confirmatory 
evidence from future welladesigned trials is warranted 
to precisely elucidate the beneficial role of bevacizumab 
in NSCLC.
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